Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Large Volume Increase – Time to Buy?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw unusually-strong trading volume on Thursday . Approximately 410,384 shares traded hands during mid-day trading, an increase of 77% from the previous session’s volume of 231,787 shares.The stock last traded at $23.15 and had previously closed at $23.28.

Wall Street Analyst Weigh In

A number of analysts have weighed in on CHGCY shares. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy”.

Chugai Pharmaceutical Trading Down 0.7%

The business’s fifty day moving average price is $25.81 and its 200 day moving average price is $27.23. The company has a market capitalization of $76.11 billion, a P/E ratio of 25.69 and a beta of 0.58.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings data on Friday, April 24th. The company reported $0.22 EPS for the quarter. The company had revenue of $2.05 billion during the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. Equities research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.